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ABSTRACT 
A new green synthesis and anti-tumor activity of the series of bis (3-arylimidazolidinyl-1) methanes 1 - 6 are described. 
The compounds were synthesized from the corresponding N-arylethylenediamine and trioxane as sources of formalde- 
hyde and the reactions were performed in heterogeneous phase catalyzed by an acidic ion-exchange resin (Amberlyst 
15). The compounds were tested with the Sulforhodamine B assay according to the protocol of the National Cancer In- 
stitute for several cell lines. The results were expressed as percentage inhibition of growth cell in comparison with the 
full growth of the cells without treatment. Cytotoxicity on normal cells using the Annexing-PI staining and flow cy- 
tometry has been evaluated. The parent compound, bis(3-phenylimidazolidinyl-1)methane 1 and the monohalogenated 
derivatives 4-chlorophenyl 3 and 3-bromophenyl 5 showed antineoplastic activity, 60%, 82% and 89% inhibition 
growth cell respectively on the human colon cell line (HCT116). The 4-tolyl derivative 6 presented inhibitory activity (73% 
inhibition of growth cell) on human lung adenocarcinoma cell line (A549) and 62% on human mammary cell line MCF-7. 
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1. Introduction 
Cancer, a diverse group of diseases characterized by un- 
controlled growth of abnormal cells, is a major world- 
wide problem. It is a fatal disease standing next to the 
cardiovascular disease in terms of mortality [1,2]. The 
characterization of novel structures that can act as more 
effective anticancer agents is still a major challenge to 
medicinal chemistry researchers [3]. 
Symmetric bis-heterocyclic derivatives have been ob- 
jects of interest due to the antitumor activities that they 
have showed. Among others, head-to-head benzimida- 
zole compounds, whose activity is attributed to different 
mechanisms of action, have been most studied [4-6]. In 
other cases, a variety of heterocyclic cores are connect- 
ed through linkers of different structural features. For 
example, bis-azepines [7], bis-isooxazoloazepanes [8], 
bisindenoquinolines [9] and bis-quinolinium compounds 
[10] have been described and evaluated. 
Another group of compounds have a simple methylene 
as linker (bis-heterocyclylmethanes). Of these, the most 
studied compounds are synthetic ring-substituted bis (3’- 
indolyl) methane (DIM) analogues [11,12]. Other com- 
pounds are characterized by the presence of two satu- 
rated 1,3-N,X-heterocycles connected by a methylene of 
general formula A for which antitumor activity has been 
described. Among them, we can mention bis-imidazoli- 
dine-2,4-dione derivatives [13,14] (X = NAr, Y = COCH2, 
Z = CO), bis-oxazolidines [15] (X = O, Y = CH2CHCH3, 
Z = CH2), and taurolidine [16,17] (a bisthiadiazine de- 
rivative) (X = NH, Y = SO2CH2CH2, Z = CH2). 
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In previous studies we reported the synthesis and anti- 
microbial activity of a series of novel bis (3-arylimida- 
zolidinyl-1) methanes 1 - 6 [18], corresponding to struc- *Corresponding author. 
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ture A (X = NAr, Y = CH2CH2, Z = CH2) with two imi- 
dazolidine cores. Imidazolidines (tetrahidroimidazoles) 
are cyclic aminals of pharmacological interest. They 
have shown fungicide, bactericide, antiviral, [19-21] anti- 
Trypanosoma cruzi [22,23] and antileshmanial activity 
[24]. Other properties such as anti-inflammatory [19], 
analgesic [19], estrogenic [25] and tumor inhibition [26, 
27] activities have been also reported. On the other hand, 
imidazolidine nucleus is also present in fused heterocyc- 
lic compounds with pharmacological activity [28]. 
In line with our ongoing studies related to the syn- 
thesis and study of imidazolidines of biological interest, 
in this work, an efficient protocol for the synthesis of bis 
(3-arylimidazolidinyl-1) methanes 1 - 6 is also described 
(Table 1). In vitro anti-tumor activity and cytotoxicity of 
synthesized compounds are also presented. 
2. Experimental Section 
2.1. General Data 
The resin was dried prior to use for 2 h at 80˚C. A mix- 
ture of a corresponding N-arylethylenediamine (2.0 
mmol), trioxane (1.0 mmol) and Amberlyst-15 (150 mg) 
in DCM (dichloromethane) anh. (10 mL) was refluxed 
for an appropriate time (15 - 30 min) as indicated by 
TLC. The catalyst was filtered and the solvent was eva- 
porated in vacuo, the obtained solid were crystallized 
from ethanol to afford compounds 1 - 6 in excellent 
yields (96% - 99%). Resin recycling: the catalyst was 
refluxed with DCM to remove any adsorbed material and 
then dried at 80˚C. 
Compounds 1 - 6 were describedpreviously [18]: the 
new yields and spectroscopic data obtained confirming 
their identity shown below. 
2.1.1. Bis (3-phenylimidazolidinyl) Methane1 
Yield: 97%. M. p. 141˚C - 143˚C. 1H-NMR (CDCl3) δ 
ppm: 3.13 (t, 4H, J = 6.31); 3.43 (t, 4H, J = 6.31); 3.46 (s, 
2H); 4.16 (s, 4H); 6.50 (d, 4H, J = 7.68); 6.71 (t, 2H, J = 
7.12); 7.24 (dd, 4H, J = 7.68, 7.12). 13C NMR δ ppm: 
45.6, 50.9, 69.0, 74.4, 111.7, 113.8, 129.2, 146.5. 
2.1.2. Bis [3-(4-methoxypheny)limidazolidinyl]  
Methane2 
Yield: 96%. M. p. 144˚C - 146˚C. 1H-NMR (CDCl3) δ 
ppm: 3.12 (t, 4H, J = 6.36); 3.37 (t, 4H, J = 6.36); 3.47 (s, 
2H); 3.75 (s, 6H); 4.12 (s, 4H); 6.50 (dd, 4H, J = 6.80, 
2.30); 6.83 (dd, 4H, J = 6.80, 2.30). 13C NMR δ ppm: 
46.4, 50.9, 69.7, 55.8, 74.7, 112.7, 114.9, 141.5.2, 151.3. 
2.1.3. Bis [3-(4-chloropheny)limidazolidinyl]  
Methane 3 
Yield: 98%. M. p. 190˚C - 192˚C. 1H-NMR (CDCl3) δ 
ppm: 3.12 (t, 4H, J = 6.27); 3.37 (t, 4H, J = 6.27); 3.44 (s, 
2H); 4.11 (s, 4H); 6.43 (d, 4H, J = 8.90); 7.17 (d, 4H, J = 
8.90). 13C NMR δ ppm: 45.8, 50.8, 69.0, 74.1, 112.6, 
121.2, 129.0, 145.2.  
2.1.4. Bis [3-(3,4-dichloropheny)limidazolidinyl] 
Methane 4 
Yield: 96%. M. p. 153˚C - 155˚C. 1H-NMR (CDCl3) δ 
ppm: 3.12 (t, 4H, J = 6.18); 3.36 (t, 4H, J = 6.18); 3.43 (s, 
2H); 4.10 (s, 4H); 6.33 (dd, 2H, J = 8.72, 2.80); 6.56 (s, 
2H), 7.23 (d, 2H, J = 8.72). 13C NMR δ ppm: 45.7, 50.7, 
68.8, 73.1, 111.2, 112. 9, 119.0, 130.5, 132.8, 145.6. 
2.1.5. Bis [3-(3-bromopheny)limidazolidinyl]  
Methane 5 
Yield: 99%. M. p. 138˚C - 140˚C. 1H-NMR (CDCl3) δ 
ppm: 3.11 (t, 4H, J = 6.42); 3.38 (t, 4H, J = 6.42); 3.43 (s, 
2H); 4.12 (s, 4H); 6.42 (dd, 2H, J = 7.95, 2.25); 6.64 (t, 
2H, J = 2.25), 6.81 (dd, 2H, J = 7.69, 2.25),7.06 (t, 2H, J 
= 7.95). 13C NMR δ ppm: 45.5, 50.7, 68.8, 74.0, 110.2, 
114.3, 119.1, 123.3, 130.4, 147.4. 
2.1.6. Bis [3-(4-methylpheny)limidazolidinyl]  
Methane 6 
Yield: 98%. M. p. 138˚C - 140˚C. 1H-NMR (CDCl3) δ 
ppm: 2.25 (s, 6H); 3.12 (t, 4H, J = 6.37); 3.39 (t, 4H, J = 
6.37); 3.46 (s, 2H); 4.14 (s, 4H); 6.47 (d, 4H, J = 8.43); 
7.04 (d, 4H, J = 8.43). 13C NMR δ ppm: 20.2, 45.9, 50.9, 
69.3, 74.6, 111.8, 125.5, 129.7, 144.6.  
2.2. Antineoplastic Screening 
Compounds 1, 2 were evaluated against 60 human cell 
lines derived from seven clinically isolated cancer types 
(lung, colon, melanoma, renal, ovarian, brain and leu- 
kemia) according to a standard protocol (conducted at the 
National Cancer Institute, Bethesda, MD, USA) with the 
sulforhodamine B (SRB) assay [29-32]. In the present 
study, it has been evaluated the anti-proliferative activity 
of the compounds 1 - 6 on human lung adenocarcinoma 
epithelial cell line A549, human colon carcinoma cell 
line HCT116 and human mammary adenocarcinoma cell 
line MCF-7 according with the NCI protocol. 
Peripheral blood was obtained from healthy donors in 
accordance with local ethical committee approval. The 
peripheral blood mononuclear cells (PBMC) were iso- 
lated by centrifugation through a Ficoll-Hypaque (Phar- 
macia LKB Biotech., Piscataway, NJ) gradient. Mono- 
nuclear cells from peripheral blood (PBMC) were cul- 
tured for 48 h in the presence of the synthesized drugs at 
a concentration of 10−4 M in culture medium RPMI con- 
taining 5% fetal bovine serum, 2 mM L-glutamine and 
gentamicin in plastic 96-multiwell plates. Controls were 
performed without the addition of the drugs or cultured 
in the presence of dimethyl sulfoxide (DMSO). After 48 
h, the cells were removed from the wells, washed with 
cold PBS and resuspended in 400 μl of cold PBS and 100 
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μl were transferred to FacScan tubes. FITC-Annexin-V 
(Becton and Dickinson) was added to the experimental 
tubes. The samples were mixed by vortex and incubated 
for 15 minutes at room temperature in the dark. PI and 
binding buffer were provided in the kit and were added 
to the samples which were analyzed within one hour by 
flow cytometry. Dot-plots of PI vs. Annexin-V fluores- 
cence were obtained with the WinMDI 2.9 program and 
percentages for each population corresponding to the live 
cells and cells that enter in apoptosis and necrosis were 
calculated. 
3. Results and Discussion 
In our original procedure compounds 1 - 6 were syn- 
thesized in homogenous phase by condensation of N-ary- 
lethylenediamines with an excess aqueous formaldehyde 
(37%) in ethanol under reflux [18]. Precursor N-ary- 
lethylenediamines were prepared by aminolysis of 2- 
bromoethylamine (hydrobromide) with the correspond- 
ing arylamine [33]. 
In recent years, heterogeneous catalysts have attracted 
attention as catalysts for a variety of organic reactions. 
The use of solid acid catalyst instead of liquids includes 
many advantages, such as reduced equipment corrosion, 
ease of product isolation, and environmental acceptabil-
ity. Amberlist-15 is a macroporous acidic ion-exchange 
resin that presents several advantages. In this regard 
Amberlyst 15 possesses properties such as non-hazard- 
ous, chemical and physical stability and can be recycled 
and used over a prolonged period. It catalyzes a wide 
variety of reactions in heterogeneous phase [24-36], and 
recently was used for the synthesis of bis (heterocyclyl) 
methane derivatives from heteroaryl species and car- 
bonyl substrates [37]. 
In this work we present the synthesis of bis-derivatives 
1 - 6 in heterogeneous phase using trioxane as source of 
formaldehyde and Amberlyst-15 as catalyst (Scheme 1). 
The reactions were performed by heating a mixture of 
the corresponding N-arylethylenediamine, trioxane and 
the resin in DCM (dichloromethane) under reflux for a 
period as indicated in Table 1. After filtration and eva- 
poration of the solvent compounds 1 - 6 were obtained 
with excellent yields (Table 1). The catalyst could be 
recycled by refluxing in DCM and consecutively reused 
after activation for tree times with similar yields. 
Bis (3-phenylimidazolidinyl-1) methane (1) and bis [3- 
(4-methoxyphenyl) imidazolidinyl-1] methane (2) were 
selected by the National Cancer Institute (NCI) for the in 
vitro cell line screening to investigate their anticancer 
activity. These compounds were evaluated against 60 
human cell lines derived from seven clinically isolated 
cancer types (lung, colon, melanoma, renal, ovarian, 
brain and leukemia) according to a standard protocol 
(conducted at the National Cancer Institute, Bethesda,  
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Scheme 1. Synthesis of bis (3-arylimidazolidinyl-1) methanes 
derivatives. 
 
Table 1. Synthesized compounds1 - 6. 
Compound R Time (min) Yield (%) 
1 H 17 96 
2 4-CH3O 19 95 
3 4-Cl 27 98 
4 3,4-Cl2 25 96 
5 3-Br 15 97 
6 4-CH3 18 95 
 
MD, USA) with the sulforhodamine B (SRB) assay 
[21-24]. The evaluated compounds 1 y 2 showed anti- 
tumor activity for the leukemia cells lines CCRF-CEM, 
K-562, MOLT-4 and RPMI 8226; for non-small cell lung 
cancer HOP-92, NCI-H23; colon cancer HCC-2998, 
HCT-15, SW-620; melanoma LOX IMVI cell line, 
IGROV1 ovarian cancer and renal cancer A486 and 
ACHN. The growth inhibitory activity and GI50 data are 
presented in Table 2. 
Considering the above results obtained for the com- 
pounds 1 and 2 it was performed the NCI assay with the 
compounds 3 - 6 on 3 different human cell lines. In our 
laboratory, it was studied the anti-proliferative activity of 
the compounds 1 - 6 on human lung adenocarcinoma 
epithelial cell line A549, human colon carcinoma cell 
line HCT116 and human mammary adenocarcinoma cell 
line MCF-7 according with the NCI protocol. Percentage 
growth inhibition was calculated as:     Ti Tz C Tz 100      for concentrations for which 
Ti ≥ Tz;  Ti Tz Tz 100     for concentrations for 
which Ti < Tz. [Tz: time zero, C: control growth, and Ti: 
test growth in the presence of drug at the five concentra- 
tion levels].Growth inhibition of 50% (GI50) was calcu- 
lated from  
   Ti Tz Tz 100 50C      ,  
which was the drug concentration resulting in a 50% re-  
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Table 2. Antiproliferative activity of compounds 1 - 2 (NCI results). 
Cell line Compound 1 Compound 2 
 %G 1 × 10−4 M GI50* %G 1 × 10−4 M GI50 
CCRF-CEM 22 4.20 × 10−5 10 3.34 × 10−5 
K-562 48 3.90 × 10−6 −50 2.78 × 10−5 
MOLT-4 37 2.36 × 10−5 −45 1.23 × 10−5 
RPMI-8226 35 6.09 × 10−5 1 3.26 × 10−5 
HOP-92 85 >1.00 × 10−4 46 8.15 × 10−5 
NCI-H23 73 >1.00 × 10−4 38 4.80 × 10−5 
HCC-2998 62 >1.00 × 10−4 38 5.04 × 10−5 
HCT-15 51 >1.00 × 10−4 11 3.70 × 10−5 
SW-620 30 6.07 × 10−5 2 2.82 × 10−5 
LOX IMVI 41 6.86 × 10−5 23 4.13 × 10−5 
IGROV1 31 2.56 × 10−5 12 1.70 × 10−6 
A498 8 3.72 × 10−5 7 1.82 × 10−5 
ACHN 30 5.40 × 10−5 −1 3.36 × 10−5 
*GI50 value is the concentration that results in 50% decrease in the cell growth relative to an untreated control. 
 
duction in the net protein increase (as measured by 
SRBstaining) in control cells during the drug incubation. 
The drug concentration resulting in total growth inhibi- 
tion (TGI) was calculated from Ti = Tz. The LC50 (con- 
centration of drug resulting in a 50% reduction in the 
measured protein at the end of the drug treatment as 
compared to that at the beginning) indicating a net loss of 
cells following treatment that was calculated from  Ti Tz Tz 100 50      . Values were calculated for 
each of these three parameters if the level of activity was 
reached; however, if the effect was not reached or was 
exceeded, the value for that parameter was expressed as 
greater or less than the maximum or minimum concen- 
tration tested. 
When the compounds 1 - 6 were assayed with different 
cell lines it was observed, in general, a potent inhibitory 
activity (Table 3 and Figures 1-3). 
In Figures 4 and 5 it is shown the dose-response 
curves for the six compounds for different drug concen- 
trations, indicating that in all the cases it is possible to 
observe a dependence of the response with the concen- 
tration. 
In order to study the apoptotic process that the cells 
suffer with the different drug treatment, it was consulted 
the Beckton and Dickinson manual for the use of An- 
nexin-V-propidium iodine. Loss of plasma membrane 
asymmetry is one of the earliest features of apoptosis: the 
membrane phospholipid phosphatidylserine (PS) is trans- 
located from the inner to the outer leaflet of the plasma 
membrane, thereby exposing PS to the external cellular 
environment. Annexin V is a 35 - 36 kDa Ca2+-depen- 
dent phospholipid-binding protein with high affinity for 
PS, and binds to exposed apoptotic cell surface PS. 
In order to test the toxicity of the drugs, it was per- 
formed an experiment to detect apoptosis and necrosis in 
peripheral blood mononuclear cells (PBMC)that can be 
considered as a normal cell population, with the Annex- 
in-V PI kit and analysis of this phenomenon by flow cy- 
tometry. The results showed that drugs 2 and 4 were 
toxic at the concentration of 10−4 M obtaining high per- 
centages of apoptosis. The other drugs showed a per- 
centage lower than 15% of apoptosis and necrosis and 
can be considered nontoxic (Figure 6). 
Results can be summarized as follows: 
Compounds 2, showed antiproliferative activity mainly 
for the cell lines studied by the NCI but they were toxic 
for normal cells (37% apoptosis). Drug 4 also presented 
the greater antineoplastic activity in the three cells lines 
showed in the Figures 1-3 but it was very toxic for nor- 
mal cells (57% apoptosis). 
Compounds 1, 3, 5 and 6 were not cytotoxic in pri- 
mary cultures of PBMC and they showed different anti- 
neoplastic activity for the studied cell lines of different 
origin. It was possible to find a correlation between the 
substitution of the compounds and the sensitivity of the 
cell lines. The parent compound, bis (3-phenylimida- 
zolidinyl-1) methane 1 showed antineoplastic activity on 
the leukemia cell lines CCRF-CEM, K562 and MOLT-4, 
on the ovarian cancer cell line A-498, on ACHN, on lung 
cell lines and on colon cell line. Nevertheless, it was not  
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Table 3. Percentage growth inhibition of compounds 1 - 6, 1 × 10−4 M. 
Cell line Compound 1 Compound 2 Compound 3 Compound 4 Compound 5 Compound 6 
A549 46% 54% 46% 74% 50% 73% 
HCT116 60% 53% 82% 100% 89% 23% 
MCF-7 9% 57% 47% 85% 46% 62% 
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Figure 1. In vitro antineoplastic activity of the drugs in 
comparison with the full growth C for the human lung ade- 
nocarcinoma A549 (n = 6). 
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Figure 2. In vitro antineoplastic activity of the drugs in 
comparison with the full growth C for the human colon 
adenocarcinoma HCT116 (n = 9). 
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Figure 3. In vitro antineoplastic activity of the drugs in 
comparison with the full growth C for the human mam- 
mary adenocarcinoma MCF-7 (n = 9). 
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Figure 4. Doses response curve for compounds 1 - 3 in a 
MCF-7 growth inhibition experiment (n = 9). 
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Figure 5. Doses response curve for compounds 4 - 6 in a 
MCF-7 growth inhibition experiment (n = 9). 
 
TOXICITY ASSAY
1 2 3 4 5 6
0
10
20
30
40
50
60
70
80
TREATMENT
%
 A
PO
PT
O
SI
S
 
Figure 6. Cytotoxicity of the experimental drugs on normal 
PBMC. The percentage of apoptosis and necrosis was de- 
termined in an Annexin-V PI assay and analyzed by flow 
cytometry (n = 3). The values for the basal without the ad- 
dition of the drugs and the control of DMSO were sub- 
stracted for each treatment. 
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possible to detect antineoplastic activity on the human 
mammary cell line MCF-7.The monohalogenated deri- 
vatives 4-chlorophenyl 3 and 3-bromophenyl 5 showed a 
similar activity on the lung (46%, 50% inhibition of 
growth cell), and mammary cell lines (47%, 46% inhibi- 
tion growth cell). These derivatives showed a potent and 
selective activity represented by 82% and 89% inhibition 
growth cell on the colon cell line. The 4-tolyl derivative 
6 presented an inhibitory activity reaching a value of 
73% inhibition of growth cell on lung adenocarcinoma 
cell line and 62% on mammary cell line. 
Considering the above results and in relation with a 
Structure Activity Correlation it was observed that a 
methyl substituent in the aromatics rings increases the 
anti-neoplastic activity on lung adenocarcinoma cell line 
(A549) and mammary cell line (MCF-7). The mono- 
substitution on the aromatics rings by halogen (chloro, 
bromo) increases selectively the activity for the human 
colon cell line (HCT116). 
4. Conclusion 
We have developed a new and simple protocol to prepare 
a series of bis (3-arylimidazolidinyl-1) methanes 1 - 6 
using trioxane as a source of formaldehyde, and Amber- 
lyst-15 as an efficient catalyst. Compounds were tested 
with the Sulforhodamine B assay according to the NCI 
assay for several cell lines and evaluated cytotoxicity on 
normal cells using the Annexin-PI staining and flow cy- 
tometry. In some cases (compounds 1, 3, 5 and 6) we 
found antineoplastic activity without toxic effects. 
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